Adapted problem adaptation therapy for depression in mild to moderate Alzheimer's disease dementia: A randomized controlled trial

被引:4
|
作者
Howard, Robert [1 ]
Cort, Elizabeth [1 ]
Rawlinson, Charlotte [1 ]
Wiegand, Martin [2 ]
Downey, Anne [2 ]
Lawrence, Vanessa [3 ]
Banerjee, Sube [4 ]
Bentham, Peter [5 ]
Fox, Chris [6 ]
Harwood, Rowan [7 ]
Hunter, Rachel [2 ]
Livingston, Gill [1 ]
Moniz-Cook, Esme [8 ]
Panca, Monica [2 ]
Raczek, Malgorzata [9 ]
Ivenso, Chineze [10 ]
Russell, Gregor [11 ]
Thomas, Alan [12 ]
Wilkinson, Philip [13 ]
Freemantle, Nicholas [14 ]
Gould, Rebecca [1 ]
机构
[1] UCL, Div Psychiat, London, England
[2] UCL, Priment Clin Trials Unit, London, England
[3] Kings Coll London, David Goldberg Ctr H1 01, London, England
[4] Univ Plymouth, Plymouth, Devon, England
[5] Birmingham & Solihull NHS Trust, Birmingham, England
[6] Univ East Anglia, Norwich, Norfolk, England
[7] Univ Nottingham, Queens Med Ctr, Nottingham, England
[8] Univ Hull, Kingston Upon Hull, England
[9] Brighton & Sussex Sch Med, Brighton, E Sussex, England
[10] Aneurin Bevan NHS Trust, St Cadocs Hosp, Newport, Wales
[11] Bradford Dist Care Fdn Trust, Bradford, England
[12] Univ Newcastle, Campus Ageing & Vital, Newcastle Upon Tyne, England
[13] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford, England
[14] UCL, Comprehens Clin Trials Unit, London, England
基金
美国国家卫生研究院;
关键词
Alzheimer's disease; clinical trial; depression; mood; problem adaptation therapy; psychological; psychotherapy; MINI-MENTAL-STATE; ANXIETY; PEOPLE; SCALE;
D O I
10.1002/alz.13766
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
INTRODUCTION: Trials of effectiveness of treatment options for depression in dementia are an important priority. METHODS: Randomized controlled trial to assess adapted Problem Adaptation Therapy (PATH) for depression in mild/moderate dementia caused by Alzheimer's disease. RESULTS: Three hundred thirty-six participants with mild or moderate dementia, >7 on Cornell Scale for Depression in Dementia (CSDD), randomized to adapted PATH or treatment as usual. Mean age 77.0 years, 39.0% males, mean Mini-Mental State Examination 21.6, mean CSDD 12.9. For primary outcome (CSDD at 6 months), no statistically significant benefit with adapted PATH on the CSDD (6 months: -0.58; 95% CI -1.71 to 0.54). The CSDD at 3 months showed a small benefit with adapted PATH (-1.38; 95% CI -2.54 to -0.21) as did the EQ-5D (-4.97; 95% CI -9.46 to -0.48). DISCUSSION: An eight-session course of adapted PATH plus two booster sessions administered within NHS dementia services was not effective treatment for depression in people with mild and moderate dementia. Future studies should examine the effect of more intensive and longer-term therapy.
引用
收藏
页码:2990 / 2999
页数:10
相关论文
共 50 条
  • [1] COST-UTILITY ANALYSIS OF ADAPTED PROBLEM ADAPTATION THERAPY FOR DEPRESSION IN MILD TO MODERATE DEMENTIA CAUSED BY ALZHEIMER'S DISEASE: PATHFINDER RANDOMIZED CONTROLLED TRIAL
    Panca, M.
    VALUE IN HEALTH, 2024, 27 (06) : S127 - S128
  • [2] Cost-utility analysis of adapted problem adaptation therapy for depression in mild-to-moderate dementia caused by Alzheimer's disease: PATHFINDER randomised controlled trial
    Panca, Monica
    Howard, Robert
    Cort, Elizabeth
    Rawlinson, Charlotte
    Gould, Rebecca L.
    Wiegand, Martin
    Downey, Anne Marie
    Banerjee, Sube
    Fox, Chris
    Harwood, Rowan
    Livingston, Gill
    Moniz-Cook, Esme
    Russell, Gregor
    Thomas, Alan
    Wilkinson, Philip
    Freemantle, Nick
    Hunter, Rachael Maree
    BJPSYCH OPEN, 2024, 10 (06):
  • [3] Acupuncture for patients with mild to moderate Alzheimer's disease: a randomized controlled trial
    Jia, Yujie
    Zhang, Xuezhu
    Yu, Jianchun
    Han, Jingxian
    Yu, Tao
    Shi, Jiangwei
    Zhao, Lan
    Nie, Kun
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2017, 17
  • [4] Acupuncture for patients with mild to moderate Alzheimer’s disease: a randomized controlled trial
    Yujie Jia
    Xuezhu Zhang
    Jianchun Yu
    Jingxian Han
    Tao Yu
    Jiangwei Shi
    Lan Zhao
    Kun Nie
    BMC Complementary and Alternative Medicine, 17
  • [5] Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease - A randomized controlled trial
    Mulnard, RI
    Cotman, CW
    Kawas, C
    van Dyck, CH
    Sano, H
    Doody, R
    Koss, E
    Pfeiffer, E
    Jin, S
    Gamst, A
    Grundman, M
    Thomas, R
    Thal, LJ
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (08): : 1007 - 1015
  • [6] Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease LEADe
    Feldman, H. H.
    Doody, R. S.
    Kivipelto, M.
    Sparks, D. L.
    Waters, D. D.
    Jones, R. W.
    Schwam, E.
    Schindler, R.
    Hey-Hadavi, J.
    DeMicco, D. A.
    Breazna, A.
    NEUROLOGY, 2010, 74 (12) : 956 - 964
  • [8] Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease
    Egan, Michael F.
    Kost, James
    Tariot, Pierre N.
    Aisen, Paul S.
    Cummings, Jeffrey L.
    Vellas, Bruno
    Sur, Cyrille
    Mukai, Yuki
    Voss, Tiffini
    Furtek, Christine
    Mahoney, Erin
    Mozley, Lyn Harper
    Vandenberghe, Rik
    Mo, Yi
    Michelson, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (18): : 1691 - 1703
  • [9] Adapting and Optimizing Problem Adaptation Therapy (PATH) for People With Mild-Moderate Dementia and Depression
    McCombie, Catherine
    Cort, Elizabeth
    Gould, Rebecca L.
    Kiosses, Dimitris N.
    Alexopoulos, George S.
    Howard, Robert
    Lawrence, Vanessa C.
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2021, 29 (02): : 192 - 203
  • [10] Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial
    Peskind, ER
    Potkin, SG
    Pomara, N
    Ott, BR
    McDonald, S
    Xie, Y
    Gergel, I
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 : S332 - S332